Mylan, Pfizer, William J. Clinton Foundation infectious news

The foundation's HIV/AIDS Initiative announced agreements with Mylan and Pfizer to offer more affordable treatments for patients in the developing world with drug-resistant HIV. Pfizer agreed to sell generic rifabutin to treat tuberculosis (TB) in patients receiving second-line antiretroviral therapy for HIV/AIDS at $1 per 150 mg dose, or $90 for a full course of treatment over six months. The price is a 60% discount and is available in developing markets in Africa, Asia, Eastern Europe, Latin America, the Middle East and the Caribbean. ...